Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsing–Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study
Background This pilot study investigated changes in remyelinating and demyelinating activity in normal appearing brain tissue (NABT) and lesions, by using voxel-wise magnetization transfer ratio (VW-MTR), in patients with relapsing–remitting multiple sclerosis (RRMS) receiving interferon beta-1a 44 mcg subcutaneously (IFN β-1a SC) three times weekly versus healthy controls (HCs) (NCT01085318). Methods Increasing (suggestive of remyelination) and decreasing (suggestive of demyelination) VW-MTR changes in NABT and in T2, T1 and gadolinium (Gd)-enhancing lesion volume were measured over 24 weeks in 23 patients treated with IFN β-1a SC and in 15 HCs (where applicable). VW-MTR changes were tested using the Wilcoxon signed–rank or Wilcoxon rank–sum test. Results A trend for greater volume of NABT with increasing VW-MTR at 24 weeks was observed for patients versus HCs (median [range] 1206 [0–15278]; 342 [0–951] mm3; p = 0.061). NABT volume with increasing VW-MTR at 12 weeks was significantly greater in patients than in HCs (852 [6–11577]; 360 [0–1755] mm3; p = 0.028). Similar findings were detected for lesion volumes. Two patients with notably high numbers of Gd-enhancing lesions at baseline had a markedly greater volume of tissue with increasing VW-MTR compared with other patients. Volume of NABT tissue with decreasing VW-MTR was significantly greater in patients versus HCs at 24 weeks (942 [0–6141]; 297 [0–852] mm3; p<0.001). Conclusions The significant change in NABT volume with increasing VW-MTR at 12 weeks suggests that active remyelination in patients with RRMS may occur during treatment with IFN β-1a SC. Findings from two patients with the highest number of Gd-enhancing lesions at baseline suggest that extensive remyelination in NABT may occur in patients with high disease activity. Tissue volume with decreasing VW-MTR was greater in patients than in HCs, despite treatment, validating the sensitivity of this technique for detecting MS disease activity. Trial Registration ClinicalTrials.gov NCT01085318.
References
[1]
Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, et al. (2003) Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 60: 1073–1081. doi: 10.1001/archneur.60.8.1073
[2]
Dutta R, Trapp BD (2007) Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68: S22–S31. doi: 10.1212/01.wnl.0000275229.13012.32
[3]
Zivadinov R (2007) Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 68: S72–S82. doi: 10.1212/01.wnl.0000275236.51129.d2
[4]
Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL (2008) Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 63: 254–262. doi: 10.1002/ana.21302
[5]
Deloire-Grassin MS, Brochet B, Quesson B, Delalande C, Dousset V, et al. (2000) In vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J Neurol Sci 178: 10–16. doi: 10.1016/s0022-510x(00)00331-2
[6]
Tjoa CW, Benedict RH, Dwyer MG, Carone DA, Zivadinov R (2008) Regional specificity of magnetization transfer imaging in multiple sclerosis. J Neuroimaging 18: 130–136. doi: 10.1111/j.1552-6569.2007.00198.x
[7]
Dwyer M, Bergsland N, Hussein S, Durfee J, Wack D, et al. (2009) A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio. J Neurol Sci 282: 86–95. doi: 10.1016/j.jns.2009.03.016
[8]
Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, et al. (2012) Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNbeta-1a in multiple sclerosis. Mult Scler 18: 1125–1134. doi: 10.1177/1352458511433304
[9]
Audoin B, Davies G, Rashid W, Fisniku L, Thompson AJ, et al. (2007) Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis. Mult Scler 13: 483–489. doi: 10.1177/1352458506070450
[10]
Brown RA, Narayanan S, Arnold DL (2012) Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. Neuroimage 66C: 103–109. doi: 10.1016/j.neuroimage.2012.10.059
[11]
Chen JT, Kuhlmann T, Jansen GH, Collins DL, Atkins HL, et al. (2007) Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage 36: 1152–1158. doi: 10.1016/j.neuroimage.2007.03.073
[12]
Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, et al. (2010) Demyelination versus remyelination in progressive multiple sclerosis. Brain 133: 2983–2998. doi: 10.1093/brain/awq250
[13]
Goldschmidt T, Antel J, Konig FB, Bruck W, Kuhlmann T (2009) Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72: 1914–1921. doi: 10.1212/wnl.0b013e3181a8260a
[14]
Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, et al. (2006) Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129: 3165–3172. doi: 10.1093/brain/awl217
[15]
Dousset V, Brochet B, Vital A, Gross C, Benazzouz A, et al. (1995) Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. AJNR Am J Neuroradiol 16: 225–231.
[16]
McCreary CR, Bjarnason TA, Skihar V, Mitchell JR, Yong VW, et al. (2009) Multiexponential T2 and magnetization transfer MRI of demyelination and remyelination in murine spinal cord. Neuroimage 45: 1173–1182. doi: 10.1016/j.neuroimage.2008.12.071
[17]
Zaaraoui W, Deloire M, Merle M, Girard C, Raffard G, et al. (2008) Monitoring demyelination and remyelination by magnetization transfer imaging in the mouse brain at 9.4 T. MAGMA. 21: 357–362. doi: 10.1007/s10334-008-0141-3
[18]
Giacomini PS, Levesque IR, Ribeiro L, Narayanan S, Francis SJ, et al. (2009) Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels. Arch Neurol 66: 375–381. doi: 10.1001/archneurol.2008.578
[19]
PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498–1504. doi: 10.1016/s0140-6736(98)03334-0
[20]
PRISMS Study Group, University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56: 1628–1636. doi: 10.1212/wnl.56.12.1628
[21]
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the “McDonald criteria”. Ann Neurol 69: 292–302. doi: 10.1002/ana.22366
[22]
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907–911. doi: 10.1212/wnl.46.4.907
[23]
Zivadinov R, Heininen-Brown M, Schirda CV, Poloni GU, Bergsland N, et al. (2012) Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage 59: 331–339. doi: 10.1016/j.neuroimage.2011.07.045
[24]
Njenga MK, Coenen MJ, DeCuir N, Yeh HY, Rodriguez M (2000) Short-term treatment with interferon-alpha/beta promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis. J Neurosci Res 59: 661–670. doi: 10.1002/(sici)1097-4547(20000301)59:5<661::aid-jnr9>3.0.co;2-e
[25]
Chen JT, Easley K, Schneider C, Nakamura K, Kidd GJ, et al. (2013) Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology 80: 246–252. doi: 10.1212/wnl.0b013e31827deb99
[26]
John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, et al. (2002) Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 8: 1115–1121. doi: 10.1038/nm781
Charles P, Reynolds R, Seilhean D, Rougon G, Aigrot MS, et al. (2002) Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain 125: 1972–1979. doi: 10.1093/brain/awf216
[29]
Vavasour IM, Laule C, Li DK, Traboulsee AL, MacKay AL (2011) Is the magnetization transfer ratio a marker for myelin in multiple sclerosis? J Magn Reson Imaging 33: 713–718. doi: 10.1002/jmri.22441
[30]
Dula AN, Gochberg DF, Valentine HL, Valentine WM, Does MD (2010) Multiexponential T2, magnetization transfer, and quantitative histology in white matter tracts of rat spinal cord. Magn Reson Med 63: 902–909. doi: 10.1002/mrm.22267
[31]
Gareau PJ, Rutt BK, Karlik SJ, Mitchell JR (2000) Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging 11: 586–595. doi: 10.1002/1522-2586(200006)11:6<586::aid-jmri3>3.0.co;2-v
[32]
Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59: 1496–1506. doi: 10.1212/01.wnl.0000034080.43681.da
[33]
Fox RJ, Beall E, Bhattacharyya P, Chen JT, Sakaie K (2011) Advanced MRI in multiple sclerosis: current status and future challenges. Neurol Clin 29: 357–380. doi: 10.1016/j.ncl.2010.12.011
